Cervix carcinoma

6 trials MedDRA PT
6 Registered trials
0 Recruiting
6 Unique sponsors
8 Unique IMPs
5 Commercial trials
Drug classes (ATC)
— ATC code not specified 3
N Neurology/Psychiatry (ATC N) 2
S Ophthalmology/ENT (ATC S) 1
L Oncology (ATC L) 1
Mechanism of action (INN-stem analysis)
Unknown / small molecule 4 substances
Corticosteroid 1 substance
Antibody-drug conjugate (ADC) 1 substance
Checkpoint inhibitor (PD-L1) 1 substance
Monoclonal antibody (angiogenesis) 1 substance
Phase III: 2 Phase II: 1 Phase I/II: 1 Phase I: 1 Phase I (First in Human): 1

Filter these 6 trials by country, sponsor, date range and more.

Open in Search → Gap analysis →
Show: 6 trials

Phase III

2 trials
  • Seagen Inc. Commercial
    BRIMONIDINE TARTRATE; DEXAMETHASONE; DEXTRAN 70, HYPROMELLOSE; TISOTUMAB VEDOTIN
    2023-503813-31-01 13 countries 2021 n=188
    Ended
  • Grupo Espanol De Investigacion En Cancer De Ovario Academic
    ATEZOLIZUMAB; BEVACIZUMAB
    2024-514179-17-00 6 countries 2018 n=339
    Ended

Phase II

1 trial
  • Daiichi Sankyo Inc. Commercial
    RALUDOTATUG DERUXTECAN
    2024-513307-13-00 5 countries 2025 n=73
    Ended

Phase I/II

1 trial
  • Genmab A/S Commercial
    TISOTUMAB VEDOTIN
    2023-508832-68-00 6 countries 2019 n=143
    Ended

Phase I

1 trial
  • Amgen Inc. Commercial
    IMP not specified
    2022-502867-39-00 3 countries 2023 n=58
    Ended

Phase I (First in Human)

1 trial
Sponsor activity
SponsorTypeTrialsPhasesRecruiting
Amgen Inc. Commercial 1 Phase I 0
Daiichi Sankyo Inc. Commercial 1 Phase II 0
Seagen Inc. Commercial 1 Phase III 0
Crescent Biopharma Inc. Commercial 1 Phase I (First in Human) 0
Genmab A/S Commercial 1 Phase I/II 0
Grupo Espanol De Investigacion En Cancer De Ovario Academic 1 Phase III 0
New trials by year
2019
1
2021
1
2023
1
2025
1
← All indication landscapes